Mosunetuzumab
- Generic Name
- Mosunetuzumab
- Brand Names
- Lunsumio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1905409-39-3
- Unique Ingredient Identifier
- LDJ89SS0YG
- Background
Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as rituximab, in co...
- Indication
Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Associated Conditions
- Relapsed or Refractory Follicular Lymphoma
- Associated Therapies
- -
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 31
- Registration Number
- NCT06594939
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Izidore Lossos, MD
- Target Recruit Count
- 35
- Registration Number
- NCT06569680
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06563505
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT06453044
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
- Conditions
- Ann Arbor Stage II Follicular LymphomaGrade 2 Follicular LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 3a Follicular LymphomaAnn Arbor Stage III Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT06442475
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 600
- Registration Number
- NCT06337318
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06015880
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 50
- Registration Number
- NCT05994235
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05961696
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.